Caprock Group LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Caprock Group LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,265 shares of the company’s stock after buying an additional 1,013 shares during the quarter. Caprock Group LLC’s holdings in Novo Nordisk A/S were worth $5,356,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. Finally, Dunhill Financial LLC grew its stake in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

NVO opened at $84.36 on Friday. The company’s 50-day simple moving average is $93.97 and its two-hundred day simple moving average is $113.62. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $378.56 billion, a P/E ratio of 27.30, a P/E/G ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.